Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Week in Review: Shanghai Regor to Discover Metabolic Therapies for Lilly in $1.55 Billion Deal

publication date: Dec 11, 2021

Deals and Financings 

  • Shanghai Regor Therapeutics entered a $1.55 billion research pact with Eli Lilly to discover novel therapies for metabolic disorders;
  • Beijing Avistone Pharma, a precision oncology company, received a $200 million strategic investment led by Vivo Capital to combine with Pearl Biotech;
  • Hangzhou Innoforce brought its Series A round to $157 million with a $59 million tranche for its biopharma development/manufacturing operations;
  • METiS Therapeutics, a Cambridge, MA AI company, raised $86 million in a Series A Round from China investors;
  • CANbridge Pharma of Shanghai completed a $77 million Hong Kong IPO to develop its rare disease candidates;
  • RareStone, a Shanghai-Boston company, in-licensed greater China rights to a therapy for genetic obesity from Rhythm Pharma in a $75 million agreement;
  • Xcovery, a Florida  biopharma backed by Hangzhou's Betta Pharma, acquired a controlling stake in Meryx, a North Carolina immuno-oncology company;
  • Tianjin CanSinoBIO partnered with Ireland's Aerogen to supply inhalers for its nasal coronavirus therapy; 

Trials and Approvals 

  • Beijing Brii Biosciences reported China approved its combination mAb therapy for patients with mild COVID-19 at risk for disease progression;
  • Shanghai I-Mab said the first patient has been dosed in a US Phase I study of Protollin, a novel immune therapy for Alzheimer's disease. 

Stock Symbols: (NYSE: LLY) (HK: 1228) (SHA: 688185, HK: 06185) (HK: 2137) (NSDQ: IMAB)

Share this with colleagues:

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Beijing and Digital
November 8-11, 2022
ChinaBio? News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022
<蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <文本链> <文本链> <文本链> <文本链> <文本链> <文本链>